ArticleiScience2026
Carboxypeptidase M deficiency aggravates complement-induced lung injury.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carboxypeptidase M (CPM) metabolizes several bioactive peptides by removing their C-terminal arginine residues. It was postulated that the substrates include the anaphylatoxins C3a and C5a generating their less active desArg forms. C3a and C5a are potent mediators of inflammation, shaping both innate and adaptive immune responses. Considering that CPM is a membrane-bound enzyme expressed in multiple organs, we hypothesized that it may protect tissues from anaphylatoxin-driven damage. Using mass spectrometry, we confirmed that CPM efficiently converts C3a and C5a into their desArg forms. We then generated CPM-deficient rats and subjected them to a complement-dependent model of acute lung injury. Compared to controls, CPM-deficient rats exhibited consistently exacerbated lung damage, including higher histological injury scores, increased neutrophil and macrophage infiltration, and elevated expression of inflammatory marker genes. These findings indicate that CPM protects the lung from complement-mediated injury and highlight it as a potential therapeutic target in inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.